Bulk Pharmaceutical API Sources for VEMLIDY

Bulk Pharmaceutical API Sources for VEMLIDY

Vendor	Vendor Homepage	Vendor Sku	API Url
AKos Consulting & Solutions		AKOS016009341
Molport		MolPort-027-835-280
AbaChemScene		CS-3366
MedChemexpress MCE		HY-15232
Sun-shine Chemical		GS-7340
BOC Sciences		379270-37-8

Bulk API Sources for VEMLIDY (Tenofovir Alafenamide Fumarate)

Last updated: February 20, 2026

VEMLIDY (tenofovir alafenamide fumarate) is an antiviral medication used in the treatment of chronic hepatitis B and HIV-1. It is a prodrug of tenofovir, designed for targeted delivery to lymphoid cells, reducing systemic exposure. Its API sourcing involves a combination of active pharmaceutical ingredient (API) manufacturing, with key suppliers operating globally.

Major API Manufacturers for Tenofovir Alafenamide (TAF)

1. Gilead Sciences Inc.

• Role: Proprietary API holder and primary supplier since VEMLIDY’s launch.
• Status: Vertically integrated; controls both the manufacturing process and supply chain.
• Production Sites: Operates manufacturing facilities in the United States and Ireland.
• Market Position: Dominates supply due to proprietary rights and extensive scale.

2. Sun Pharmaceutical Industries Ltd.

• Operations: Produces tenofovir alafenamide API under licensing or partnership agreements.
• Facilities: Ghaziabad, India, with capacity for bulk API production.
• Supply Chain: Supplies to generic manufacturers under approved licensing.

3. Cipla Limited

• Scope: Manufactures TAF API for generic markets.
• Facilities: Located in India; complies with global GMP standards.
• Supply Role: Supplies API mainly for markets outside the U.S.

4. Hetero Drugs Ltd.

• Production Capability: Produces tenofovir alafenamide API for the Indian and emerging markets.
• Quality: Follows stringent quality standards compatible with international regulations.

5. Other Notable Suppliers

• Viatris (formerly Mylan): Has shifted to API sourcing from multiple manufacturers under licensing agreements.
• Strides Pharma Science: Provides TAF API as part of their HIV treatment portfolio.

API Manufacturing Process Overview

• Raw Materials: Starts with nucleoside analog building blocks and phosphonate intermediates.
• Synthesis: Multi-step chemical synthesis involving protection/deprotection, phosphorylation, and salt formation.
• Quality Control: API must meet specifications for purity (>99%), residual solvents, heavy metals, and process impurities.
• Regulatory Compliance: GMP standards adhered to across all manufacturing sites.

Sourcing Comparison Table

Manufacturer	Location	Capacity	Key Markets	Licensing	GMP Status
Gilead (VEMLIDY)	US, Ireland	High	Global	Proprietary	Yes
Sun Pharma	India	Moderate	Global (licensed)	Yes	Yes
Cipla	India	Moderate	Global (licensed)	Yes	Yes
Hetero	India	Moderate	Emerging markets	Yes	Yes
Viatris	Global	Variable	Global	Licensing	Yes
Strides Pharma	India	Moderate	Emerging markets	Yes	Yes

Supply Chain Dynamics

• Gilead retains the majority market share for VEMLIDY through proprietary manufacturing.
• India-based generics manufacturers supply TAF API mainly for markets outside the U.S.
• Licensing agreements enable multiple manufacturers to produce TAF API, increasing market stability.
• API quality must meet strict international standards to ensure regulatory approval.

Regulatory and Patent Status

• Gilead holds foundational patents on TAF, expiring in various jurisdictions between 2023 and 2030.
• Indian manufacturers have secured compulsory licenses or patent challenges in certain regions.
• Regulatory filings demand comprehensive documentation of manufacturing processes, quality controls, and supply chain verifications.

Pricing and Cost Considerations

• Gilead's proprietary API costs are higher, reflecting R&D and manufacturing investments.
• Generic API manufacturers compete with lower-cost options, especially before patent expiry.
• API prices vary based on volume, purity, and regional regulatory requirements.

Future Trends in API Sourcing

• Increased API production capacity in India and China to support generic and biosimilar markets.
• Technology transfer agreements to expand manufacturing capacity.
• Focus on digitalization and quality automation to improve yield and compliance.
• Potential stockpiling by generic manufacturers ahead of patent cliffs.

---

Key Takeaways

• Gilead Arts holds the primary API rights for VEMLIDY.
• Indian generic manufacturers, including Sun Pharma and Cipla, produce TAF API for non-U.S. markets.
• Multiple licensing agreements diversify the supply chain but do not fundamentally change Gilead's market dominance.
• Thailand, India, and China are key regional sources for bulk TAF API.
• API costs differ significantly between proprietary and generic sources, impacting global market pricing.

---

Frequently Asked Questions

1. Who are the main API manufacturers for VEMLIDY?
Gilead (proprietary), Sun Pharma, Cipla, and Hetero are key producers, with Gilead holding exclusive rights and others supplying generics under licensing.

2. How does patent status affect API sourcing?
Patents restrict generic production until expiry; licensing agreements allow generic manufacturers to produce TAF API legally in certain jurisdictions, expanding supply options.

3. What regions are primary sources of TAF API?
US and Ireland for Gilead; India and China for generic manufacturers.

4. How does API quality impact drug safety and efficacy?
Manufacturers must comply with GMP standards, ensuring purity (>99%), minimal residual solvents, and correct salt forms, critical for drug safety.

5. What trends could influence future API sourcing for VEMLIDY?
Patent expiries, capacity expansions in India and China, and technological innovations in synthesis processes.

---

Sources

[1] U.S. Food and Drug Administration. (2022). Approved drug products with therapeutic equivalence evaluations.
[2] Gilead Sciences Inc. Annual Reports. (2022).
[3] Indian Drug Manufacturers Association. (2023). API manufacturing capabilities.
[4] World Health Organization. (2021). Guidelines on quality assurance of pharmaceuticals.
[5] European Medicines Agency. (2022). Regulatory requirements for APIs.